NL 201

Drug Profile

NL 201

Alternative Names: mIL-11; Mutein interleukin-11; NL 002; NL-201; VM-501

Latest Information Update: 21 Jun 2016

Price : $50

At a glance

  • Originator Beijing Northland Biotech
  • Developer Beijing Northland Biotech; ViroMed
  • Class Chemoprotectants; Interleukins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Haematopoiesis stimulants; Interleukin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombocytopenia

Highest Development Phases

  • Phase III Thrombocytopenia
  • Preclinical Blood coagulation disorders

Most Recent Events

  • 21 Jun 2016 Preclinical trials in Coagulation disorders in China (SC) before June 2016
  • 15 Feb 2016 NDR Project - ADS for ph III trial; added CTP for NCT01663441; as per Viromed website, ph III development is still ongoing (http://viromed.co.kr/main/sub02_01_3.html; http://viromed.co.kr/main/sub02_01.html; http://viromed.co.kr/main/sub02_02.html)
  • 15 Feb 2016 NL 201 is still in phase III development for Thrombocytopenia (chemotherapy-induced) in China (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top